Larimar Therapeutics announced dosing of the first patient in an open label extension, or OLE, study evaluating 25 mg daily subcutaneous injections of nomlabofusp in participants with Friedreich’s ataxia, or FA. Nomlabofusp is a novel protein replacement therapy designed to address the root cause of Friedreich’s ataxia by delivering frataxin to mitochondria.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LRMR:
- Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia
- Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference
- Largest borrow rate increases among liquid names
- Larimar Therapeutics, Inc. (LRMR) Q4 Earnings Cheat Sheet
- Insider Trading: Larimar’s (NASDAQ:LRMR) Director Makes an Enormous Purchase
